← All trials
NCT05796089
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2022
- Primary completion
- Sep 30, 2027
- Completion date
- Feb 28, 2028
- First posted
- Apr 3, 2023
- Last posted
- Sep 7, 2023
- Enrollment
- 35
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Trans Tasman Radiation Oncology GroupLead sponsor
- AstraZenecaCollaborator
- Austin HealthOverall official - principal investigator
- Austin HealthOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.